This week’s MedTech lineup spans major financings and meaningful progress across multiple therapeutic areas. Companies developing advanced thrombectomy systems, vascular-access implants, heart-failure therapies, and AI-powered cancer diagnostics all secured new backing, alongside novel approaches...
Atraverse Medical announced that it received FDA clearance for its fully integrated Hotwire transseptal access system.
Hotwire is a novel radiofrequency guidewire left-heart access device....
Kestra Medical Technologies announced that it priced an upsized underwritten offering worth approximately $138 million.
The Kirkland, Washington-based company said its offering includes 6 million...
Francis Medical’s Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug Administration (FDA).
Vanquish is a transurethral, ultrasound...
JenaValve announced new results from an expanded patient cohort supporting the use of its Trilogy transcatheter heart valve (THV) system.
Results from the ALIGN-AR pivotal...
Vexev and U.S. Renal Care announced successful results from the CANSCAN trial of the VxWave robotic ultrasound imaging system. Sydney, Australia-based Vexev develops the...
Hyperion Surgical announced today that it completed the world’s first robotic-assisted intravenous (IV) catheterisation using its Ivy platform.
Ivy integrates advanced imaging, AI and robotic...
AtriCure, a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced...
Atraverse Medical announced that it received FDA clearance for its fully integrated Hotwire transseptal access system.
Hotwire is a novel radiofrequency guidewire left-heart access device....
Kestra Medical Technologies announced that it priced an upsized underwritten offering worth approximately $138 million.
The Kirkland, Washington-based company said its offering includes 6 million...
Francis Medical’s Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug Administration (FDA).
Vanquish is a transurethral, ultrasound...